ClinicalTrials.gg

Pneumonia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,568 studies for Pneumonia across more than 10 countries. 267 are recruiting or about to start. 660 of them are mainly about Pneumonia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 12 narrower conditions too, such as COVID-19: 10,618 studies, 1,061 open.

ClinicalTrials.gov finds 11,391 studies for Pneumonia. How that becomes 1,564 here

This page counts the studies the registry files under Pneumonia, and those it files under no condition that list Pneumoniathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 11,391Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −8,722Filed under a narrower condition, counted on its own pageCOVID-19 7,363 · Post-Acute COVID-19 Syndrome 396 · Pneumonia, Ventilator-Associated 349 · Community-Acquired Pneumonia 220 · Pneumonia, Pneumocystis 96 · Pneumonia, Bacterial 71 · 5 more
  3. −143List Pneumonia as a condition, but the registry did not file them under itMost often written as “Covid-19 Pneumonia” (22), “Non-Tuberculous Mycobacterial Pneumonia” (11), and “Interstitial Pneumonia” (8). The registry filed 2 of them under no condition at all, and the others under other conditions only, most often Lung Diseases, Interstitial (29) and Idiopathic Pulmonary Fibrosis (22).
  4. −962Match it another way170 name it in the title, 37 in a keyword, and 755 by a synonym or other text the search reads.
  5. 1,564The count on this page173 of them list Pneumonia in their own words; the registry filed them under no condition.

Status

Completed
859
Status unknown
257
Recruiting
158
Not yet recruiting
101
Terminated
99
Withdrawn
41

Phase

Phase 2
207
Phase 3
203
Phase 4
125
Phase 1
86
Early Phase 1
16

Where

United States
344
China
141
France
138
Italy
83
Spain
79
United Kingdom
61

Who develops what

Add Pneumonia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 9 companies, 4 with this as their studies’ main aim; 4 with a live phase 3 study; 8 primary completions in the next 12 months. Compare Colgate Palmolive, Pfizer and BioNTech here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Sodium FluorideRecent, limited
Evidence
  • NCT07807397 · Colgate Palmolive · Phase 4 · live · background · “sodium fluoride Mouthwash” · registered Sep 2026
GlaxoSmithKline69% of its industry studies11 study
BoostrixRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07730450 · BioNTech SE · Phase 4 · live · comparator · “Tdap Vaccine” · registered Jul 2026
GlaxoSmithKline80% of its industry studies11 study
Pneumococcal 20-Valent Conjugate VaccineRecent, limited
Evidence
  • NCT07425392 · Vaxcyte, Inc. · Phase 3 · comparator · “PCV20” · registered Feb 2026
  • NCT07284654 · Vaxcyte, Inc. · Phase 3 · comparator · “PCV20” · registered Dec 2025
Pfizer82% of its industry studies12 studies

9 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (8)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Dec 2026 est.pirfenidone · GNI Group Ltd. · Phase 3 named, not the main aimNCT07388680 Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia — primary endpoint: Phase II and Phase III: The absolute value of the change in the predicted percentage of lung carbon monoxide diffusion capacity (DLCO% predicted) from the baseline at week 24. · 298 enrolled
  • 21 Apr 2027 est.BNT162 Vaccine · BioNTech SE · Phase 3 named, not the main aimNCT07798648 A Study of COVID-19 Vaccine(s) in Children and Adults — primary endpoint: Percentage of participants reporting local reactions or systemic events · 700 enrolled
  • Jun 2027 est.Allogeneic Invariant Natural Killer T-cells agenT-797 · MiNK Therapeutics · Phase 2 main aimNCT07615010 A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure — primary endpoint: Number of Deaths (All-cause Mortality) · 90 enrolled

5 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Pneumonia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · JAK inhibitors 3 open · Corticosteroids 2 open · NSAIDs 2 open · Bronchodilators 1 open

Coming up

77studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 158 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger. 41 (26%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 24 (15%) take healthy volunteers.

Recruiting studies that take each age, of 158
AgeWomenMen
1024 (15%)24 (15%)
18119 (75%)119 (75%)
30117 (74%)117 (74%)
40120 (76%)120 (76%)
50120 (76%)120 (76%)
65123 (78%)123 (78%)
75116 (73%)116 (73%)
85103 (65%)103 (65%)

Across all 1,568 studies, recruiting or not: 28% stop at 75 or younger and 25% at 65; 29% take children; 1% are for women only and <1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pneumonia studies take

Of 67 phase 3 interventional studies under Pneumonia, half reached primary completion within 17 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo6–34 · 35 studies——
Phase 214 mo7–28 · 64 studies—11 mo6–28 · 39 studies
Phase 317 mo8–38 · 67 studies16 mo7–32 · 26 studies26 mo9–59 · 41 studies
Phase 431 mo21–40 · 49 studies—33 mo21–43 · 42 studies
Interventional, no phase21 mo10–31 · 266 studies—21 mo11–31 · 259 studies
Observational27 mo13–53 · 223 studies—27 mo14–57 · 210 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,568. Browse all 1,568 → or search them.